For its first fiscal quarter (ending March 31), Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has reported a -110% decline in E.P.S. from $0.30 a year ago to $-0.03 in the current quarter. This performance was $-0.17 short of the consensus estimate of $0.14. E.P.S. were $-6.78 for the latest four quarters through March 31 versus $1.19 for the same period a year ago — a decline of -670%.
Recent Price Action
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) stock suffered a major decline of -17.0% on 5/9/24. The shares closed at $6.74. Moreover, unusually high trading volume at 177% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -18.0% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, IRWD is expected to be a major Value Eraser.
Ironwood Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment